Literature DB >> 25584139

Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a serious concern or red herring?

Meena K Singh1, Marc Avram1.   

Abstract

The use of finasteride for the treatment of male pattern hair loss has recently been the focus of media and internet attention for potential irreversible sexual dysfunction and severe depression. The purpose of this study was to perform a critical review of the recent studies reporting prolonged sexual dysfunction and depression with the use of finasteride for the treatment of male pattern hair loss. A literature search was performed using PubMed to review the literature pertaining to any potential adverse effects with the use of finasteride and its treatment of male pattern hair loss. The authors conclude that the reports of potential irreversible sexual dysfunction and severe depression do raise concerns about the safety of finasteride; however, these studies are wrought with significant bias. Therefore, larger, randomized, double blind, controlled trials are warranted to further ascertain the true potential risks or confirm long-term safety profile of finasteride use.

Entities:  

Year:  2014        PMID: 25584139      PMCID: PMC4285451     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  20 in total

1.  Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia.

Authors: 
Journal:  Eur J Dermatol       Date:  2002 Jan-Feb       Impact factor: 3.328

2.  Finasteride in the treatment of men with frontal male pattern hair loss.

Authors:  J Leyden; F Dunlap; B Miller; P Winters; M Lebwohl; D Hecker; S Kraus; H Baldwin; A Shalita; Z Draelos; M Markou; D Thiboutot; M Rapaport; S Kang; T Kelly; D Pariser; G Webster; M Hordinsky; R Rietschel; H I Katz; L Terranella; S Best; E Round; J Waldstreicher
Journal:  J Am Acad Dermatol       Date:  1999-06       Impact factor: 11.527

3.  Persistent sexual side effects of finasteride for male pattern hair loss.

Authors:  Michael S Irwig; Swapna Kolukula
Journal:  J Sex Med       Date:  2011-03-18       Impact factor: 3.802

4.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

Authors:  J D McConnell; R Bruskewitz; P Walsh; G Andriole; M Lieber; H L Holtgrewe; P Albertsen; C G Roehrborn; J C Nickel; D Z Wang; A M Taylor; J Waldstreicher
Journal:  N Engl J Med       Date:  1998-02-26       Impact factor: 91.245

5.  Finasteride increases anagen hair in men with androgenetic alopecia.

Authors:  D Van Neste; V Fuh; P Sanchez-Pedreno; E Lopez-Bran; H Wolff; D Whiting; J Roberts; D Kopera; J J Stene; S Calvieri; A Tosti; E Prens; M Guarrera; P Kanojia; W He; K D Kaufman
Journal:  Br J Dermatol       Date:  2000-10       Impact factor: 9.302

6.  Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group.

Authors:  K D Kaufman; E A Olsen; D Whiting; R Savin; R DeVillez; W Bergfeld; V H Price; D Van Neste; J L Roberts; M Hordinsky; J Shapiro; B Binkowitz; G J Gormley
Journal:  J Am Acad Dermatol       Date:  1998-10       Impact factor: 11.527

7.  Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.

Authors:  E Stoner
Journal:  Arch Intern Med       Date:  1994-01-10

8.  Finasteride for the treatment and control of benign prostatic hyperplasia: summary of phase III controlled studies. The Finasteride Study Group.

Authors:  P Grino; E Stoner
Journal:  Eur Urol       Date:  1994       Impact factor: 20.096

9.  Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia.

Authors:  E Stoner
Journal:  Urology       Date:  1994-03       Impact factor: 2.649

10.  Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.

Authors:  Hunter Wessells; Johnny Roy; John Bannow; John Grayhack; Alvin M Matsumoto; Lisa Tenover; Richard Herlihy; William Fitch; Richard Labasky; Stephen Auerbach; Raul Parra; Jacob Rajfer; Jennifer Culbertson; Michael Lee; Mark A Bach; Joanne Waldstreicher
Journal:  Urology       Date:  2003-03       Impact factor: 2.649

View more
  8 in total

Review 1.  Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?

Authors:  Abdulmaged M Traish; Roberto Cosimo Melcangi; Marco Bortolato; Luis M Garcia-Segura; Michael Zitzmann
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

Review 2.  Androgenetic Alopecia: An Update of Treatment Options.

Authors:  Yanna Kelly; Aline Blanco; Antonella Tosti
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

3.  Relationships between cerebrospinal fluid GABAergic neurosteroid levels and symptom severity in men with PTSD.

Authors:  Ann M Rasmusson; Matthew W King; Ivan Valovski; Kristin Gregor; Erica Scioli-Salter; Suzanne L Pineles; Mohamed Hamouda; Yael I Nillni; George M Anderson; Graziano Pinna
Journal:  Psychoneuroendocrinology       Date:  2018-11-22       Impact factor: 4.905

Review 4.  Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.

Authors:  Jason M Hirshburg; Petra A Kelsey; Chelsea A Therrien; A Carlo Gavino; Jason S Reichenberg
Journal:  J Clin Aesthet Dermatol       Date:  2016-07-01

Review 5.  Recent advances in treatment for Benign Prostatic Hyperplasia.

Authors:  Simon van Rij; Peter Gilling
Journal:  F1000Res       Date:  2015-12-21

6.  Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.

Authors:  B M Piraccini; U Blume-Peytavi; F Scarci; J M Jansat; M Falqués; R Otero; M L Tamarit; J Galván; V Tebbs; E Massana
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-10-25       Impact factor: 9.228

7.  Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride.

Authors:  Tina Kiguradze; William H Temps; Steven M Belknap; Paul R Yarnold; John Cashy; Robert E Brannigan; Beatrice Nardone; Giuseppe Micali; Dennis Paul West
Journal:  PeerJ       Date:  2017-03-09       Impact factor: 2.984

Review 8.  Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia.

Authors:  Yu Seob Shin; Keshab Kumar Karna; Bo Ram Choi; Jong Kwan Park
Journal:  World J Mens Health       Date:  2018-08-10       Impact factor: 5.400

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.